References of "Revue du Praticien (La)"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLes gliptines, une nouvelle mode?
SCHEEN, André ULg

in Revue du Praticien (La) (2013), 63(3), 304-5

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailAdénome hypophysaire
VROONEN, Laurent ULg; Beckers, Albert ULg

in Revue du Praticien (La) (2011)

Detailed reference viewed: 18 (6 ULg)
Full Text
Peer Reviewed
See detailLes statines dans la prise en charge des dyslipidémies
SCHEEN, André ULg

in Revue du Praticien (La) (2011), 61(8), 1120-1126

Statins, combined with life-style advices, have a key position in the prevention of cardiovascular diseases. By inhibiting HMG-CoA reductase enzyme, these medications reduce total and LDL cholesterol ... [more ▼]

Statins, combined with life-style advices, have a key position in the prevention of cardiovascular diseases. By inhibiting HMG-CoA reductase enzyme, these medications reduce total and LDL cholesterol levels in a dose-dependent manner. They also exert various pleiotropic effects that may contribute to the cardiovascular protection. Although some differences exist between available statins, a class effect seems predominant. Statins have proven their efficacy in numerous controlled randomized trials (recently pooled in meta-analyses), both in primary and secondary prevention, including various specific populations, among them patients with diabetes. Tolerance and safety profile is rather good even if muscular and hepatic adverse events may occur. The prescription of statins should target high-risk individuals and both therapeutic inertia and drug non-compliance should be avoided. [less ▲]

Detailed reference viewed: 136 (0 ULg)
Full Text
Peer Reviewed
See detailAlternatives medicamenteuses aux statines.
SCHEEN, André ULg

in Revue du Praticien (La) (2011), 61(8), 1121-2

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailUtilisation thérapeutique de l'érythropoïétine
Beguin, Yves ULg

in Revue du Praticien (La) (2009), 59

Detailed reference viewed: 42 (9 ULg)
Full Text
Peer Reviewed
See detailLe sang de cordon ombilical
Beguin, Yves ULg

in Revue du Praticien (La) (2008), 58

Detailed reference viewed: 36 (4 ULg)
Full Text
Peer Reviewed
See detailAdénome hypophysaire
Vroonen, Laurent ULg; Beckers, Albert ULg

in Revue du Praticien (La) (2007), 57(8), 881-6

Detailed reference viewed: 11 (6 ULg)
Full Text
Peer Reviewed
See detailTomographie a emission de positons: un premier bilan.
Jerusalem, Guy ULg; Withofs, Nadia ULg; Rorive, Andrée ULg et al

in Revue du Praticien (La) (2007), 57(17), 1864-70

Positron emission tomography (PET) has been widely used for several years for staging and response evaluation in oncology. It is time to critically review its role in routine patient care. [18F]-labelled ... [more ▼]

Positron emission tomography (PET) has been widely used for several years for staging and response evaluation in oncology. It is time to critically review its role in routine patient care. [18F]-labelled fluorodeoxyglucose ([18F]-FDG) remains the radiotracer of choice in most indications. Its high sensitivity, the half-life of 110 minutes and the easy production of this radiotracer explain its routine use although the specificity is not very good. Infectious or inflammatory processes can mimic tumours. Appropriate selection of patients studied in the recommended indications and interpretation of images by an experienced team having access to both clinical information and other diagnostic studies allows reducing the risk of false positives. Although PET is highly accurate, not all patients suffering from cancer need a PET study. Major improvements were also observed with conventional imaging techniques over the past 10 years. It is important to avoid long waiting lists because otherwise treatment delay may counterbalance the benefit of PET studies. [less ▲]

Detailed reference viewed: 38 (2 ULg)
Full Text
Peer Reviewed
See detailLes offrandes liées à la fécondité et à la maternité dans la Gaule romaine
Nissen, Cécile ULg

in Revue du Praticien (La) (2006), 56(7), 804-9

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailTomographie a emission de positons: une revolution en cancerologie?
Jerusalem, Guy ULg; Hustinx, Roland ULg

in Revue du Praticien (La) (2003), 53(15), 1629-30

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailEffets de l'interleukine 1 sur les chondrocytes humains cultivés en agrégats
Bassleer, Corinne; Jaspar, Jean-Marie; Reginster, Jean-Yves ULg et al

in Revue du Praticien (La) (1996), 46(6 Spec No), 31-34

Detailed reference viewed: 22 (6 ULg)
Full Text
Peer Reviewed
See detailInterleukine 1 et métabolisme osseux
Reginster, Jean-Yves ULg; Zheng, SX

in Revue du Praticien (La) (1996), 46

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailAutres médiateurs de l'inflammation et du sepsis
Lamy, Maurice ULg; Deby, Ginette ULg; Damas, Pierre ULg

in Revue du Praticien (La) (1993), 43(1), 19-25

During sepsis, the systemic inflammatory response is characterized by the release of numerous mediators supporting and dispersing inflammation. In Gram negative sepsis, the endotoxins play a starting role ... [more ▼]

During sepsis, the systemic inflammatory response is characterized by the release of numerous mediators supporting and dispersing inflammation. In Gram negative sepsis, the endotoxins play a starting role, while in other sepsis, the triggering mediators or mechanisms are unknown but lead to a similar inflammatory reaction. Coagulation and complement cascades are activated, with the release of chemoattractive substances, mediators and proteases and the activation of phagocytic cells. Macrophages/monocytes and polymorphonuclear leucocytes produce then active oxygen species and cytokines; they degranulate (releasing active enzymes such as myeloperoxidase), they express an increasing number of membrane receptors able to interact with endothelial cells and release a supplementary lot of inflammatory mediators (prostanoids, platelet activating factor, leukotrienes ... ). Platelets, also activated, produce the same mediators (TXA2, PAF ...) or specific ones such as serotonine, platelet factor 4, growth factors. Last, but not least, the endothelial cells are stimulated, directly (by endotoxins) or undirectly (by cytokines, C5a, PAF ...). These cells play then a main role by their own phagocytic activity, by alteration of their antithrombotic and fibrinolytic potential, by their secretion of inflammatory mediators and by an increased expression of receptors of adhesivity for the activated phagocytes or platelets, what leads to endothelium injury with membrane permeability alterations. These cascades of activation, these extensions of the inflammatory reaction by the mediators and by the phagocytes and platelets can explain the frequency of multiple organ failure during sepsis as well as the difficulty of an adequate pharmacological therapy. [less ▲]

Detailed reference viewed: 27 (1 ULg)